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Innate inflammatory responses are crucial for induction and regulation of T  cell and 
antibody responses. Mast cell (MC)-deficient Kit mutant mice showed impaired adaptive 
immunity, suggesting that MCs provide essential adjuvant activities, and pharmacologi-
cal MC activation was proposed as a new adjuvant principle. However, the Kit mutations 
result in complex alterations of the immune system in addition to MC deficiency. We 
revisited the role of MCs in vaccination responses using Mcpt5-Cre R26DTA/DTA and 
Cpa3Cre/+ mice that lack connective tissue MCs or all MCs, respectively, but feature 
an otherwise normal immune system. These animals showed no impairment of T and 
B cell responses to intradermal vaccination with protein antigen plus complete Freund’s 
adjuvant. Moreover, we demonstrate that the adjuvant effects of the MC secretagogue 
c48/80 in intradermal or mucosal immunization are independent of the presence of MCs. 
We hence find no evidence for a regulation by MCs of adaptive immune responses to 
protein antigens. The finding that immunological MC functions differ from those sug-
gested by experiments in Kit mutants, emphasizes the importance of rigorous tests in 
Kit-independent MC-deficiency models.
Keywords: mast cells, adaptive immune responses, vaccination, adjuvant, compound 48/80
inTrODUcTiOn
Understanding the interplay of cellular and molecular factors involved in induction and regulation 
of adaptive immune responses is crucial to promote diverse areas of medicine including control of 
infectious disease, vaccine development, and immunotherapy of cancer. Dendritic cells (DCs), the 
most important antigen-presenting cells, represent the central switch controlling T cell, and thereby 
also B cell responses. DCs reside in peripheral tissues where they sample their environment. They 
sense microbial infection by means of pattern-recognition receptors (PRRs) which detect micro-
bial structures [pathogen-associated molecular patterns (PAMPs)] as well as molecular changes 
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associated with cell stress and cell death caused by the infection 
as a measure of how severe a threat an infection poses [danger-
associated molecular patterns (DAMPs)] (1). DCs integrate PRR 
signals and, depending on the outcome of this process, migrate 
to draining LNs, upregulate their antigen-presentation machin-
ery and increase expression of co-stimulatory molecules and 
cytokines, thereby providing essential signals for T cell activation 
and differentiation in the LN. The intensity and quality of PRR 
and cytokine signals the DC received in the tissue determines 
intensity and quality of the T cell response it drives in the LN (1).
Dendritic cells also respond to cytokines and other factors that 
tissue cells secrete upon detection of PAMPs or DAMPs. Mast 
cells (MCs) are tissue-resident hematopoietic cells that, like DCs, 
can express a wide array of PRRs and potentially release impor-
tant immunostimulatory mediators. MCs are located in most 
tissues but their numbers are highest at inner and outer body 
surfaces suggesting a role in defense against environmental chal-
lenges. MCs were reported to be critical promoters of adaptive 
immunity that provide adjuvant effects through rapid provision 
of histamin and TNF, thereby boosting DC activation, DC migra-
tion to draining LNs, and lymphocyte homing to LNs (2–11). 
Moreover, MCs themselves were suggested to migrate to tissue-
draining LNs and contribute to the initiation of adaptive immune 
responses by directly serving as antigen-presenting cells (12–18). 
Pharmacological MC activation was proposed as a novel adjuvant 
principle for vaccination (19). In keeping with these studies, 
important roles in diverse physiological and pathogenic immune 
responses have been attributed to MCs (20–25). However, these 
studies, which collectively built a view of the MC as an important 
regulator/amplifier of local innate responses that adjuvants 
adaptive immunity, were largely based on experiments in mutant 
mouse strains that are MC-deficient because of hypomorphic 
expression of the receptor tyrosin kinase Kit, the receptor for the 
growth factor stem cell factor. Since compromised Kit expression 
affects multiple hematopoietic and other lineages (26–29), phe-
notypes of Kit mutant strains are not necessarily the consequence 
of the absence of MCs. Reconstitution of Kit mutants with MCs 
differentiated from bone marrow cells in  vitro (BMMCs) has 
been widely used as an argument that a phenotype was caused by 
MC deficiency (30). However, the many observed inconsisten-
cies in results obtained in Kit mutants and BMMC reconstitu-
tions therein, and Kit-independent MC-deficient mutants (see 
below) show that Kit mutants replete with BMMCs have been an 
unreliable experimental system. While Kit mutant strains were 
a common tool for the investigation of MC functions over the 
past decades, novel mouse models with intact Kit expression were 
recently developed, in which MC deficiency was achieved by dif-
ferent principles (31–34). Cpa3Cre/+ mice (32) express high levels 
of Cre recombinase that eliminate MCs and a fraction of baso-
phils through Cre-mediated genotoxicity and a p53-dependent 
damage response (32). These animals are completely devoid of 
MCs and feature a reduction of basophil numbers to 40%. In 
Mcpt5-Cre R26DTA/DTA mice (31, 35), expression of Cre recombi-
nase is controlled by the mast cell protease (Mcpt) 5 promoter 
and thereby restricted to connective tissue mast cells (CTMCs). 
Cre recombinase deletes a loxP-flanked stop cassette of the R26DTA 
knock in allele (36), which results in subsequent expression of 
diphtheria toxin A (DTA) selectively in CTMCs, which thereby 
kill themselves. As a consequence, Mcpt5-Cre R26DTA/DTA mice 
constitutively lack CTMCs, while mucosal MCs are unaffected. 
In both strains, IgE-mediated systemic anaphylaxis is abrogated, 
consistent with lack of MCs (32, 35). However, when other MC 
in vivo functions identified earlier in the Kit mutant models were 
revisited in the new, Kit-independent strains, phenotypes of the 
Kit mutants were not reproducible in many instances (31, 32, 34, 
35, 37–46). These findings suggested that reduced Kit expression 
in the hematopoietic system rather than MC deficiency was 
responsible for some of the immunological phenotypes of the 
Kit mutant strains (40), and called for a systematic reproduction 
of key experiments in the new, Kit-independent MC-deficiency 
models. The aim of this study was to revisit the role of MCs in 
vaccination responses.
resUlTs
in E. coli-infected Tissue, Mcs are not 
required for hypertrophy of Draining 
lymph nodes
To study the role of MCs in adaptive immune responses, we used 
the Mcpt5-Cre R26DTA/DTA system (31, 35) to generate mice with 
selective deficiency for CTMCs. For maximum efficiency of MC 
depletion, we bred the ROSA26-DTA knock in allele (R26DTA) to 
homozygosity. Mcpt5-Cre R26DTA/DTA mice featured virtually com-
plete absence of CTMCs in peritoneal cavity and skin without 
alteration of other hematopoietic cell subsets in peritoneum, skin, 
spleen, bone marrow, or blood as determined by flow cytometry 
and histology (Figure S1 in Supplementary Material). We had 
earlier shown highly efficient depletion of skin MCs on formalin-
fixed, Giemsa-stained sections (47). As mucosal MCs of the intes-
tinal tract can be metachromatically stained using special fixation 
procedures like Carnoy fixation but not after formalin fixation, 
we now performed additional Giemsa staining of Carnoy-fixed 
skin to exclude the presence of skin MC populations that fail to 
stain with conventional protocols (Figure S1 in Supplementary 
Material) and confirmed near complete absence of MCs in the 
skin of Mcpt5-Cre R26DTA/DTA mice.
We first investigated the impact of MCs on stimulation of 
the adaptive immune system by comparing LN hypertrophy in 
response to bacterial tissue infection in the presence or absence of 
MCs. McLachlan et al. described that injection of uropathogenic 
E. coli into the footpad of control mice resulted in a marked 
increase in total cellularity of the draining popliteal LN (3). LN 
hypertrophy was diminished in MC-deficient KitW/W-v mice; how-
ever, the response was restored by reconstitution of the animals 
with wild-type BMMCs. We injected the same uropathogenic 
E.  coli strain J96 into the footpad of Mcpt5-Cre+R26DTA/DTA and 
Cre-negative littermates. Saline injected animals served as 
controls. 24  h after infection, the E. coli-injected Cre-negative 
controls displayed a substantial increase in popliteal LN size 
(data not shown) and total cellularity with increased numbers 
of T  cells, B  cells, and DCs compared with the saline injected 
group as expected (Figure 1A). To our surprise, LN hypertrophy 
was not reduced in E. coli-injected Mcpt5-Cre+R26DTA/DTA animals, 
FigUre 1 | Hypertrophy of LNs draining E. coli-infected tissue does not 
depend on mast cells (MCs). (a) Total LN cellularity and absolute size of 
different cell populations of the ipsilateral popliteal LN analyzed 24 h after 
injection of 1 × 105 E. coli J96 into the hind footpad of Cre-negative R26DTA/DTA 
(n = 9) and Mcpt5-Cre+R26DTA/DTA mice (n = 10). Four Cre-negative control 
mice were injected with saline. Data from two independent experiments with 
similar results. Means ± SD are shown. (B) Numbers of MCs in E. coli 
J96-infected or saline-injected footpad tissue of the animals in (a) 24 h after 
infection as determined by histological analysis of Giemsa-stained tissue 
sections. Means ± SD are shown. In all cases, statistical analysis was 
performed using one-way ANOVA and Bonferroni’s multiple comparison test.
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but in fact, total cellularity and T cell, B cell, and DC numbers 
were even increased compared with the Cre-negative controls 
(Figure 1A). MCs were virtually absent in the infected footpad 
tissue of Mcpt5-Cre+R26DTA/DTA mice 24 h after infection as verified 
by histology (Figure  1B). Collectively, these data demonstrate 
that the recruitment of lymphocytes and DCs to LNs draining the 
footpad tissue inflamed by the innate response to bacterial infec-
tion did not require the presence of MCs in the infected tissue.
absence of Mcs Does not impair 
expansion of antigen-specific T cells in 
response to Vaccination With Peptide and 
adjuvant
We first tested whether absence of MCs affects T cell responses. 
We used the model antigen 2W1S, a variant of peptide 52–68 
from the MHC II I-Eα chain, which is not expressed and therefore 
immunogenic in C57BL/6 mice (48). Mcpt5-Cre+R26DTA/DTA and 
control mice were injected intradermally with this peptide along 
with CFA at the tail base. Inguinal LN cellularity and the antigen-
specific T cell response were monitored thereafter.
The LNs of mice injected with CFA in addition to 2W1S 
peptide showed substantial increases in total cellularity compared 
with saline-injected controls 3, 7, and 21 days after immuniza-
tion that reflected increased numbers of T cells, B cells, and DCs 
(Figure 2A; Figure S2A in Supplementary Material). Peptide alone 
had no effect on LN cellularity. As in the case of E. coli infection 
(see above, Figure  1), MC deficiency in Mcpt5-Cre+R26DTA/DTA  
mice did not impair LN hypertrophy responses to intradermal 
immunization with antigen plus adjuvant. On the contrary, the 
increase in LN cell numbers was even more pronounced in the 
absence of MCs.
In parallel to LN hypertrophy, numbers of 2W1S peptide-
specific CD4+ T cells were monitored by MHC class II tetramer 
labeling after immunization. For verification of the specificity 
of this staining, we immunized WT mice with 2W1S/CFA and 
stained total lymph node cells with 2W1S/MHC II tetramer-APC, 
flow cytometrically sorted tetramer-positive and tetramer-nega-
tive CD4+ T cells (Figure S2B in Supplementary Material) and 
restimulated them with 2W1S peptide in co-cultures with total 
LN cells of unimmunized WT mice. IFN-γ concentrations in the 
culture supernatant were quantified as a measure for T cell activa-
tion. High amounts of IFN-γ were released by tetramer-positive 
but not by tetramer-negative cells (Figure S2C in Supplementary 
Material), indicating that the tetramer indeed identified 2W1S-
specific T cells. Robust increases of 2W1S-specific T cell num-
bers were induced by immunization with 2W1S peptide plus 
CFA. Importantly, this increase was not diminished but even 
was slightly more pronounced in MC-deficient compared with 
MC-competent Cre-negative control mice at all three time points 
analyzed (day 3, 7, and 21 after immunization, Figure 2B).
To verify MC deficiency at the dermal immunization site 
of Mcpt5-Cre+R26DTA/DTA mice, and exclude that the inflam-
matory adjuvant stimulus had led to reappearance of MCs, 
dermal tissue was sampled from untreated mice and at day 21 
after immunization and MCs were counted in tissue sections. 
Figures 2C,D show that MCs were depleted with high efficiency 
in Mcpt5-Cre+R26DTA/DTA animals as expected. The local inflam-
matory response to CFA induced an increase in MC numbers in 
control but not Mcpt5-Cre+ R26DTA/DTA mice.
Collectively, these results demonstrate that MCs are not 
required for the expansion of antigen-specific T cells in response 
to immunization with peptide plus adjuvant.
absence of Mcs Does not affect antigen-
specific humoral immune responses to 
Vaccination
To study antibody responses in the presence or absence of 
MCs, Mcpt5-Cre+R26DTA/DTA and Cre-negative control mice 
were immunized intradermally with chicken ovalbumin (Ova) 
plus CFA at the tail base and serum was collected 10, 21, and 
42 days later. Serum concentrations of Ova-specific IgG of major 
murine subclasses (IgG1, IgG2b, and IgG2c) were determined by 
ELISA (Figures 3A–C). Ova alone induced no or only moderate 
immune responses that were not diminished in the MC-deficient 
animals compared with control mice. Administration of Ova plus 
CFA resulted in robust increases in anti-Ova IgG1 and IgG2b 
already 10  days after immunization, while the IgG2c response 
began somewhat later. By day 21, anti-Ova IgG1 and IgG2b had 
increased further and ranged 3–4 orders of magnitude higher, 
compared with mice that received Ova alone, by day 42 after 
immunization. The responses of MC-deficient animals were 
in the same range or even slightly enhanced in comparison to 
MC-proficient Cre-negative controls at all time points analyzed.
FigUre 2 | The antigen-specific T cell response is not diminished in mast cell (MC)-deficient mice. (a) Mcpt5-Cre+R26DTA/DTA mice and Cre-negative littermates were 
immunized with 2W1S peptide alone or peptide plus CFA by intradermal injection at the tail base (2W1S: n = 5 both groups; 2W1S/CFA: Cre− n = 11/Cre+ n = 12) 
and lymph node cellularity was assessed 3 days (see Figure S2 in Supplementary Material), 7 days, and 21 days (see Figure S2 in Supplementary Material) later. 
Saline-injected Cre-negative littermates served as additional controls. (B) Numbers of 2W1S-specific T cells in the LNs from A [time points as in (a)] were quantified 
by MHC II tetramer staining. (c,D) Efficient MC depletion of the dermal immunization site at the tail base was verified by histological analysis of Giemsa-stained skin 
sections in untreated mice (c) and at day 21 after immunization (D) (scale bar 100 µm, inset 10 µm). Dermal MCs were counted per 20-mm length of epidermis for 
each mouse. N = 7 per group at day 0; n = 4 Cre-negative saline controls, n = 5 2W1S both groups; n = 9 Cre−/n = 8 Cre+ 2W1S/CFA at day 21; means ± SD are 
shown. Data were collected from at least four independent experiments per time point. Statistical analysis was performed using one-way ANOVA and Bonferroni’s 
multiple comparison test (a,B,D) or unpaired two-sided Student’s t-test (c).
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To exclude that tissue inflammation induced by CFA resulted 
in recruitment of MCs at the immunization site even in Mcpt5-
Cre+R26DTA/DTA mice, we counted MCs in Giemsa-stained sections 
of paraffin-embedded tail base skin, sampled from the injection 
site at day 42. As shown in Figure 3D, the CFA stimulus indeed 
resulted in a doubling of MC numbers at the immunization site 
in Cre–negative control mice, while MCs were absent or very low 
in number in Mcpt5-Cre+R26DTA/DTA mice without or with CFA 
administration. Using the Carnoy fixation protocol, however, we 
found a small population of residual MCs in LNs (but not skin, see 
Figure S1F in Supplementary Material) of Mcpt5-Cre+R26DTA/DTA 
mice that was not detectable with conventional formalin fixation.
To formally exclude that this small, residual population 
of LN MCs mediated potent immunostimulatory effects that 
might explain the absence of detectable immunological deficits 
in Mcpt5-Cre+R26DTA/DTA mice, we repeated immunizations 
in Cpa3Cre/+ mice, which are completely devoid of MCs (32). 
Absence of MCs in skin and LNs of this strain was verified by 
Giemsa staining of Carnoy-fixed sections of skin tissue obtained 
from untreated mice and of LN tissue sampled at the end of the 
experiment (Figures S3A,B in Supplementary Material). Cpa3Cre/+ 
mice and Cpa3+/+ littermate controls were immunized with Ova 
plus CFA at the tail base. Serum was collected 10, 21, and 42 days 
later and concentrations of Ova-specific IgG1 and IgG2b were 
determined by ELISA (Figures 3E,F). Administration of Ova plus 
CFA to Cpa3Cre/+ mice and littermate controls resulted in increases 
of anti-Ova IgG1 and IgG2b similar to the results obtained in 
Mcpt5-Cre R26DTA/DTA mice (Figures 3A,B). The intensity of this 
humoral immune response was not altered by the absence of MCs 
in Cpa3Cre/+ littermates.
FigUre 3 | No impairment of humoral immune responses in mast cell (MC)-deficient mice. (a–c) Quantification of anti-Ova IgG1 (a), IgG2b (B), and IgG2c (c) by 
ELISA in the serum of saline treated Cre-controls (n = 12) and MC-deficient Mcpt5-Cre+R26DTA/DTA mice and Cre-negative littermates immunized intradermally with 
Ova alone or Ova plus CFA (Ova alone Cre+ n = 10, Cre− n = 10; Ova plus CFA Cre+ n = 11, Cre− n = 10). Two independent experiments were performed and yielded 
similar results. (D) MCs were counted in Giemsa-stained sections of tail base skin samples taken from each animal represented in (a–c) at day 42 after immunization 
per 20 mm length of epidermis. Means ± SD are shown. In all cases, statistical analysis was performed using one-way ANOVA and Bonferroni’s multiple comparison 
test. (e,F) Quantification of anti-Ova IgG1 (e) and IgG2b (F) by ELISA in the serum of saline treated controls (Cpa3+/+ n = 4, Cpa3Cre/+ n = 3) and MC-deficient 
Cpa3Cre/+ mice and MC-proficient Cpa3+/+ littermates immunized intradermally with Ova plus CFA (n = 7 both groups). A single experiment was performed.
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We also studied the antigen-specific antibody response to 
another antigen, protective antigen (PA) of Bacillus anthracis 
in Mcpt5-Cre R26DTA/wt mice heterozygous for the R26DTA allele. 
In these mice, MCs in skin tissue of the tail base 42 days after 
immunization were less efficiently reduced to 40% of normal 
numbers or lower (Figure S3D in Supplementary Material), 
demonstrating the impact of the zygosity of the R26DTA allele. 
The reduction of MCs by 60% or more did not impair the 
PA-specific antibody response (Figure S3C in Supplementary 
Material).
Mast cell-derived TNF was reported to be a critical mediator 
of MC effects on adaptive immunity (7). In parallel to our experi-
ments in mice lacking MCs, we directly addressed the role of 
TNF secretion by MCs using mice with normal MC numbers but 
highly efficient, selective inactivation of the TNF gene in CTMCs 
(49). Mcpt5-Cre TNFFL/FL and Cre-negative littermate control mice 
were injected with Ova plus CFA intradermally at the tail base 
and serum was collected at different time points. Figure S3E in 
Supplementary Material shows that Ova-specific IgG responses 
were not compromised in mice lacking TNF selectively in MCs 
FigUre 4 | Mast cells (MCs) are not required for c48/80-mediated LN hypertrophy. (a) Cellularity of popliteal LNs 24 h after injection of c48/80 into footpads of 
Mcpt5-Cre+R26DTA/DTA and Cre-negative littermate control mice (n = 11 both groups) as well as KitW/W–v (n = 5) and congenic Kit+/+ control animals (n = 7) as 
determined by flow cytometry. Saline injected Cre-negative mice (n = 6) served as controls. Data from two independent experiments with similar results.  
(B) Cellularity of popliteal LNs 24 h after injection of c48/80 into footpads of Cpa3Cre/+ and Cpa3+/+ littermate control mice (Cpa3+/+ n = 16, Cpa3Cre/+ n = 11) as 
determined by flow cytometry. Saline was injected as control into one of both paws. A single experiment was performed. In all cases, means ± SD are shown and 
statistical analysis was performed using one-way ANOVA and Bonferroni’s multiple comparison test.
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compared with Cre-negative control mice at the 10 and 21 day 
time points. A slight (albeit statistically significant) reduction of 
specific IgG1 but not IgG2b was observed in the mutants com-
pared to controls.
Collectively, we show that absence of MCs does not result in 
relevant impairment of antibody responses to immunization with 
protein antigen plus adjuvant.
The adjuvant effects of Mc-activating 
compound 48/80 are independent of Mcs
Compound 48/80 (c48/80) triggers MC degranulation and was 
shown to induce hypertrophy of draining LNs upon injection 
into tissues and to potently enhance adaptive immune responses 
against protein antigens. c48/80 was also described to be an effi-
cient, non-toxic adjuvant for administration along with immu-
nizing antigen via mucosal surfaces (19, 50, 51). The adjuvant 
effects of c48/80 were reduced in MC-deficient KitW/W-v mice and 
reported to be dependent on MC-derived TNF (3, 7). Therefore, 
activation of TNF release from MCs by compounds that directly 
induce MC degranulation was proposed as a new principle of 
adjuvanting adaptive immune responses (19).
To investigate the adjuvant effects of c48/80 in our MC- 
deficiency model, we first injected c48/80 alone into the footpads 
of Mcpt5-Cre+R26DTA/DTA and Cre-negative littermate control mice 
and analyzed the draining popliteal LNs 24 h later. c48/80 induced 
significant LN hypertrophy in Cre-negative mice compared with 
saline-injected controls with increases in numbers of T  cells, 
B  cells, and DCs. Of note, LN hypertrophy was not reduced in 
MC-deficient Mcpt5–Cre+R26DTA/DTA animals but, on the con-
trary, was even enhanced compared with the responses of their 
MC-proficient littermates (Figure 4A). Highly efficient MC deple-
tion in the injected tissue was verified histologically (Figure S4A 
in Supplementary Material). We next tested the effect of c48/80 
in KitW/W-v and congenic littermate control Kit+/+ mice and repro-
duced the results of published studies (19) that described impaired 
c48/80-induced LN hypertrophy in KitW/W-v mice (Figure 4A).
To exclude that residual LN MCs were responsible for the 
undiminished LN responses of Mcpt5-Cre+R26DTA/DTA mice, we 
repeated the c48/80 footpad injections in Cpa3Cre/+ mice and 
Cpa3+/+ littermate controls. Compared with the contralateral 
LNs draining the saline-injected footpad c48/80 induced sig-
nificant LN hypertrophy including increased T cell, B cell, and 
DC numbers (Figure  4B). Confirming the results obtained in 
MC-deficient Mcpt5-Cre+R26DTA/DTA animals, LN hypertrophy 
was not reduced in Cpa3Cre/+ mice but was even slightly enhanced 
compared to MC-proficient Cpa3+/+ mice.
To investigate the impact of MC deficiency on c48/80-induced 
adaptive immune responses, we immunized Mcpt5-Cre R26DTA/DTA 
mice with antigen (2W1S peptide or Ova) alone or with antigen 
plus c48/80 intradermally at the tail base and analyzed the antigen-
specific T cell and antibody responses. Numbers of 2W1S-specific 
CD4+ T  cells identified by tetramer staining were increased in 
control animals that had received 2W1S peptide plus c48/80 
compared to mice immunized with peptide alone (Figure  5A). 
This finding clearly demonstrates that c48/80 has potent adjuvant 
FigUre 5 | Mast cells (MCs) are dispensable for c48/80-induced antigen-specific T cell and antibody responses. (a,B) Cre-negative and Mcpt5-Cre+R26DTA/DTA 
mice were intradermally injected with antigen (2W1S or Ova) alone, with antigen plus c48/80 or with saline. (a) Total numbers of 2W1S-specific CD4+ T cells 
identified by tetramer staining in inguinal LNs 7 (saline n = 7; 2W1S alone n = 5 both groups; 2W1S plus c48/80 Cre+ n = 11, Cre− n = 10) or 21 days after 
immunization (saline n = 4; 2W1S alone n = 5 both groups; 2W1S plus c48/80 n = 7 both groups). (B) Quantification of anti-Ova IgG1 by ELISA in the serum of 
saline treated Cre-negative controls (n = 12) and mice immunized i.d. with Ova alone or with Ova plus c48/80 (Ova alone n = 10 both groups; Ova plus c48/80 Cre+ 
n = 9, Cre− n = 10). Data from two independent experiments with similar results. (c,D) Antigen alone (2W1S or Ova) or antigen plus c48/80 was administered into 
both nostrils of Cre-negative and Mcpt5-Cre+R26DTA/DTA mice. (c) Total cellularity and 2W1S-specific (tetramer+) CD4+ T cells were quantified flow cytometrically in 
draining mandibular LNs 21 days after immunization (saline n = 5; 2W1S alone Cre+ n = 6, Cre− n = 5; 2W1S plus c48/80 n = 6 both groups). (D) Quantification of 
anti-Ova IgG1 by ELISA in the serum of saline treated Cre-negative controls (n = 11) and mice immunized intranasally with Ova alone or with Ova plus c48/80 (Ova 
alone Cre+ n = 13, Cre− n = 12; Ova plus c48/80 n = 13 both groups). Data from three independent experiments that yielded similar results. (e) Quantification of 
anti-Ova IgG1 by ELISA in the serum of saline-treated control animals (Cpa3+/+ n = 4, Cpa3Cre/+ n = 3) and MC-deficient Cpa3Cre/+ mice and Cpa3+/+ littermates 
immunized intradermally with Ova plus c48/80 (Cpa3+/+ n = 7, Cpa3Cre/+ n = 6). A single experiment was performed. (F) Quantification of anti-Ova IgG1 by ELISA in 
the serum of saline treated controls (Cpa3+/+ n = 6, Cpa3Cre/+ n = 3) and mice immunized intranasally with Ova plus c48/80 (Cpa3+/+ n = 9, Cpa3Cre/+ n = 6). A single 
experiment was performed. In all cases, means ± SD are shown, and statistical analysis was performed using one-way ANOVA and Bonferroni’s multiple 
comparison test.
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activity. However, this effect of c48/80 is independent of MCs 
since no reduction of this activity was observed in MC-deficient 
Mcpt5-Cre+R26DTA/DTA mice (Figure  5A). Immunization with 
Ova alone only modestly induced anti-Ova IgG1, while Ova-
specific antibody concentrations increased by 2 orders of mag-
nitude 42  days after injection of Ova plus c48/80 (Figure  5B), 
indicating robust adjuvant effects. MC deficiency in Mcpt5- 
Cre+R26DTA/DTA mice, however, did not compromise c48/80 
adjuvant activity (Figure 5B). MC numbers were determined for 
each Mcpt5-Cre+R26DTA/DTA animal at the end of these experiments 
(Figure S4B in Supplementary Material).
C48/80 has been described as a potent non-toxic adjuvant for 
immunization via the nasal mucosa, suggesting that the numer-
ous connective tissue MCs surrounding the nasal-associated 
lymphatic tissue (NALT) can be activated by c48/80 to stimulate 
adaptive immunity (19). Intranasally administrated c48/80 was 
shown to induce degranulation of these CTMCs in the vicinity of 
the NALT (19). We verified by histology that this MC population 
was absent in the nasal mucosa of Mcpt5-Cre+R26DTA/DTA mice 
(Figure S4C in Supplementary Material). Efficient depletion 
of CTMCs in Mcpt5-Cre+R26DTA/DTA nasal tissue was further 
underpinned by quantification of mRNA of the CTMC-specific 
endogenous Mcpt5 gene, which we found undetectable or 
strongly reduced compared with control tissue (Figure S4E in 
Supplementary Material).
We applied antigen (2W1S or Ova) alone or along with c48/80 
into the nostrils of MC-deficient Mcpt5-Cre+R26DTA/DTA mice and 
Cre-negative littermate control mice and analyzed the draining 
mandibular LNs by flow cytometry. While 2W1S peptide alone 
had no effects, mice that received 2W1S plus c48/80 featured 
increased numbers of total lymphocytes and DCs as well as 
2W1S-specific (tetramer+) T  cells in these LNs compared to 
saline-injected controls (Figure  5C). Likewise, administration 
of Ova along with c48/80 increased Ova-specific IgG1 about 
100-fold compared with levels of mice that received Ova alone 
(Figure 5D). These findings further confirm the adjuvant quali-
ties of c48/80. However, the stimulation of antigen-specific T and 
B cell responses by c48/80 was independent of the presence or 
absence of MCs (Figures 5C,D).
Administration of Ova without adjuvant via the nasal route 
resulted in modest IgG1 responses. Under such conditions of low 
intensity of danger signals, one might expect that MCs might be 
critical providers of adjuvant effects. However, also the antibody 
response to Ova alone was not reduced in MC-deficient versus 
control mice.
We made sure that MC deficiency of the nasal tissue persisted 
for the duration of the experiment (Figure S4D in Supplementary 
Material) and also excluded that the nasal mucosa contained 
mucosal type MCs (expressing Mcpt1) that in principle are 
not amenable to depletion in Mcpt5–Cre+R26DTA/DTA animals 
and might contribute to c48/80 adjuvant effects (Figure S4E in 
Supplementary Material).
To rule out effects of residual LN MCs in Mcpt5-Cre+R26DTA/DTA, 
we repeated intradermal and intranasal immunizations with 
Ova plus c48/80 in Cpa3Cre/+ and Cpa3+/+ littermate control 
mice. We showed that nasal tissue of Cpa3Cre/+ mice was devoid 
of MCs, by demonstrating the absence of Mcpt1 and Mcpt5 
transcripts (Figure S4E in Supplementary Material). As in Mcpt5- 
Cre R26DTA/DTA mice, Ova plus c48/80 induced an increase in anti-
Ova IgG1 in both groups. These responses were not diminished 
in MC-deficient Cpa3Cre/+ mice (Figures 5E,F).
Collectively, we demonstrate that presence or absence of MCs 
has no impact on the adjuvant effects of c48/80, which must 
therefore mediate these effects via other cell types.
DiscUssiOn
The past two decades brought the exciting insight that adaptive 
immunity critically depends on innate immune responses of the 
tissues, which has tremendous impact on vaccine design and 
development of novel adjuvants (52, 53). Innate tissue responses 
determine, whether or not T and B cell responses are mounted 
and also regulate the effector class of the T and antibody response 
(1). The information on the tissue response is carried to the 
draining LN by DCs. Most tissue cells can contribute to the 
innate response in an infected tissue. MCs express several PRRs 
and are capable of releasing proinflammatory mediators (54, 
55). Several of these, including the potently immunostimulatory 
cytokine TNF, are stored in the MCs’ secretory granules and 
can be rapidly released upon activation of the MC (55). TNF-
containing MC particles were shown to reach draining LNs (2). 
The concept of the MC as an amplifier of innate immunity that 
provides adjuvant activity for adaptive responses was critically 
based on findings in Kit-mutant MC-deficient mice. LNs of 
KitW/W-v mice draining sites of E. coli infection showed reduced 
hypertrophy responses compared to LNs of wild-type mice (3). 
This phenotype was reversed by reconstitution of the infection 
site with in vitro differentiated wild-type, but not TNF-deficient 
MCs, which has been interpreted to suggest that MCs promote 
recruitment and retention of lymphocytes in LNs draining 
infected tissues by release of TNF (3). Impaired antigen-specific 
humoral responses were observed in KitW-sh/W-sh and KitW/W-v mice 
(7) and pharmacologic MC activation by MC secretagogues, 
including c48/80, was proposed as a new adjuvant principle in 
vaccination (19, 56).
However, using Mcpt5-Cre R26DTA/DTA mice that are profoundly 
deficient for connective tissue MCs but otherwise bear a normal 
immune system, we found no evidence for a MC function in 
adaptive immune responses. Compared with wild-type controls, 
the LN hypertrophy response to footpad infection with E. coli 
was unchanged in the MC-deficient animals, as were expansion 
of antigen-specific T cells and antibody responses upon vaccina-
tion with protein antigen plus CFA. The undiminished B  cell 
response also indicated that T helper effector function was not 
compromised in the absence of MCs. We confirmed unimpaired 
humoral responses in the Cpa3Cre/+ mouse model of MC deficiency 
in which complete absence of all types of MCs was extensively 
documented (32). These mice also lack the small population of 
residual MCs that we detected in LNs of Mcpt5-Cre+R26DTA/DTA 
mice. Regarding compound c48/80, a well known stimulator of 
MC degranulation, we confirmed its adjuvant activity, but found 
that this adjuvant effect was not mediated by activation of MCs. 
C48/80 induced rapid LN hypertrophy that was unaffected by MC 
deficiency in Mcpt5-Cre+R26DTA/DTA or in Cpa3Cre/+ mice. Adaptive 
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responses to intradermal or intranasal immunization with 
antigen were clearly enhanced by coadministration of c48/80 in 
MC-competent control mice. These responses were not reduced 
by the deficiency for MCs in Mcpt5-Cre+R26DTA/DTA or in Cpa3Cre/+ 
mice. Our results demonstrate that the adjuvant activity of 
c48/80 must be mediated by activating effects on cell types other 
than MCs. Compound 48/80 was shown to act on the Mrgprb2 
receptor (57), which was reported to be expressed selectively in 
MCs (58). However, c48/80 impacts additional pathways also in 
non-MCs (59, 60) and the full spectrum of c48/80 effects outside 
the MC lineage is probably not fully understood. Our findings 
of undiminished adaptive responses despite MC deficiency are 
in line with the report by Feyerabend et al. of normal humoral 
responses, including immunoglobulin class switching and hyper-
mutation, of Cpa3Cre/+ mice to i.p. immunization with antigen plus 
alum (32).
Our study adds to a long list of cases in which results in Kit 
mutant mouse strains did not reproduce in one of the novel 
mouse strains with Kit-independent selective MC deficiency but 
otherwise normal immune system, despite reported reversion 
of phenotypes of Kit mutants by reconstitution with in vitro dif-
ferentiated MCs (31, 32, 34, 35, 37, 39, 40, 42, 44–46) [reviewed in 
Ref. (38, 41, 43)]. Collectively, our results strongly suggest that Kit 
mutants are unreliable models of MC deficiency, even when com-
bined with MC reconstitutions. MC reconstitution with poorly 
defined in  vitro differentiated cells, transferred into recipients 
that feature a broadly abnormal immune system and empty MC 
niches results in a complex situation that may be the cause of mis-
leading data. While we formally cannot exclude a contribution of 
differences in genetic backgrounds to the discrepancies between 
our results in Mcpt5-Cre R26DTA/DTA and published studies using 
Kit-mutant strains, background differences were clearly ruled out 
as an explanation of conflicting results obtained in Kit mutants 
versus the Kit-independent MC-deficiency model Cpa3Cre/+ in 
another study (40). Moreover, adaptive immune responses are 
most commonly studied in C57BL/6 mice, which were in our 
case MC deficient.
The question of a MC contribution to adaptive immune 
responses has been addressed previously also in the context 
of autoimmunity. Experimental autoimmune encephalomy-
elitis (EAE) is a mouse model for multiple sclerosis in which 
CNS inflammation is induced by immunization of mice with 
brain-specific proteins plus CFA. While reduced EAE severity 
was observed in KitW/W-v mice (61, 62) and enhanced EAE was 
found in the KitW-sh/W-sh mice (63, 64), no alteration of EAE was 
detected in either of these strains in another study (65). Kit-
independent MC deficiency in Cpa3Cre/+ mice had no effect on 
EAE (32). In a model of antibody-induced arthritis, KitW-sh/W-sh 
mice develop full disease, whereas KitW/W-v animals are resistant 
to experimental joint inflammation (66, 67), demonstrating that 
perturbations of the immune system due to hypomorphic Kit 
expression beyond their MC deficiency hamper interpretations 
of findings in Kit mutant mice. Kit-independent mouse models 
of MC cell deficiency did not reveal any role for MCs in this 
arthritis model (32, 68, 69). In collagen-induced arthritis (CIA), 
in which a breakdown of self-tolerance is induced by injec-
tion of collagen along with CFA into mice (70), a pathogenic 
contribution of MCs is conceivable on the level of induction 
of the adaptive anti-collagen response as well as on the level of 
the final organ damage. MCs functions in CIA were addressed 
in the KitW-sh/W-sh strain, which was found fully susceptible (71), 
while mice deficient for Mcpt 4 featured reduced arthritis scores 
(72). Based on experiments in the Kit-independent, inducible 
Mcpt5-Cre R26iDTR/iDTR MC-deficiency model on the moderately 
CIA susceptible background C57BL/6, Schubert et al. reported a 
role for MCs in CIA (68) and observed diminished anti-collagen 
T cell responses in the absence of MCs. A recent study reported 
a reduction of CIA in (C57BL/6 × DBA/1) F1 hybrid mice with 
inducible MC and basophil deficiency dependent on the time 
point of MC depletion (73). More recently, we backcrossed the 
Mcpt5-Cre-based MC-deficiency models to the CIA susceptible 
background DBA/1 for five generations and found no significant 
reduction of joint inflammation in these animals as yet (Figure 
S5 in Supplementary Material). Thus, more experiments are 
required to definitively settle the question of MC contributions 
to arthritis in this model.
Our results do not exclude that MCs play important roles in 
the induction of adaptive responses in contexts that remain to be 
identified. A special case of adaptive responses in which MC con-
tributions play a role are pathogenic T cell responses to contact 
allergens. Such contact sensitizers are small chemicals that rap-
idly react with proteins and thereby render them immunogenic, 
a process called haptenization. The T  cell response against the 
haptenized proteins depends on a rapid activation of an innate 
inflammatory response that these sensitizing chemicals induce 
(74). How contact allergens trigger this initial innate response 
remains unknown, but activation of MCs seems to play a role 
(31, 34, 49).
In line with a concept of MC- or basophil-mediated immune 
regulation, targeted inactivation of histamine receptors was 
shown to result in altered T cell polarization upon immunization 
with OVA and adjuvant (75). Moreover, effects of IgE-mediated 
MC activation on adaptive immunity are well documented (11). 
However, MC contributions to adaptive responses are much more 
restricted than previously concluded from experiments in Kit-
mutant strains. MCs play no role in “standard” immune responses 
in situations with abundant danger signals for DC activation, but 
might serve to fill special functional gaps in the repertoire of 
mammalian innate responses. They might play a role for adap-
tive immunity under particular conditions of limiting danger 
signal intensities. The studies performed in Kit-independent 
MC-deficiency models indicate that potential functions of MCs 
in regulation of adaptive immunity, beyond pathophysiological 
functions in IgE-mediated allergic disease and delayed type 
hypersensitivity responses to exogenous chemicals, remain to be 
demonstrated.
MaTerials anD MeThODs
Mice
All mice were housed at the Experimental Center, Medical Faculty 
Carl Gustav Carus, TU Dresden, under specific pathogen-free 
conditions. 8- to 21-week-old mice were used. Littermates 
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were used as controls. All procedures were in accordance with 
institutional guidelines on animal welfare and were approved 
by the Landesdirektion Dresden (DD24-5131/207/2 and 
DD24-5131/207/33).
immunizations and E. coli infections
Ovalbumin (Catalog No. A2512), c48/80, and CFA (containing 
1 mg/ml Mycobacterium tuberculosis) were obtained from Sigma-
Aldrich. 2W1S peptide (sequence: EAWGALANWAVDSA) was 
kindly provided by Dr. J. B. McLachlan, New Orleans. Anthrax 
PA was obtained from List Biological Laboratories. All reagents 
were finally dissolved in sterile 0.9% saline. For intradermal 
immunization, each mouse was injected with 50 µl of a 10 ng/µl 
solution of the respective antigen (OVA, PA, or 2W1S peptide) 
with or without 0.6  µg/µl c48/80. Half of these 50  µl were 
injected intradermally at each side of the tail base. When CFA 
was used as an adjuvant, 0.5  µg antigen (OVA, PA, or 2W1S 
peptide) were dissolved in 25 µl saline and emulsified with 25 µl 
CFA/mouse (1:1 emulsion). Half of these 50 µl were injected at 
each side of the tail base. For mucosal immunization, mice were 
anesthetized with isoflurane and 10 µg of antigen or antigen plus 
30 µg c48/80 were administered nasally at day 0, 7, and 14 in a 
total volume of 15 µl/mouse (7.5 µl into each nostril). For analy-
sis of LN hypertrophy upon injection of c48/80, 2.4 µg/g body 
weight of c48/80 were dissolved in a volume of 40 µl. Half of this 
volume was injected subcutaneously into each hind footpad of 
one mouse. As negative controls, additional mice were injected 
with 20 µl of saline into each hind footpad. For analysis of LN 
hypertrophy in Cpa3Cre/+ mice, one hind footpad was injected 
with c48/80, the other with saline (20 µl each). Uropathogenic 
E. coli J96 (ATCC 700336) were purchased from LGC Standards 
(Wesel, Germany). From an overnight culture in Luria–Bertani 
(LB) broth, bacteria were grown again in LB broth to an A600 of 
0.6 where they reached the exponential phase. Bacterial cultures 
yielded about 1 × 107 viable cells/ml. E. coli were washed twice 
and dissolved in sterile saline. 1 × 105 E. coli in a volume of 20 µl 
were injected into each hind footpad of one mouse. As negative 
controls, additional mice were injected with 20 µl of saline into 
each hind footpad.
Quantification of ln hypertrophy and 
2W1s-specific T cells
Inguinal LNs were isolated at day 3, 7, or 21 after immuniza-
tion with 2W1S plus adjuvant and single cell suspensions were 
generated by crushing between glass slides. APC-coupled 
2W1S-MHC class II tetramer was kindly provided by Dr. J. B. 
McLachlan, Department of Microbiology and Immunology, 
Tulane University School of Medicine, New Orleans. Isolated 
cells were resuspended in 2% BSA/PBS and incubated with 
2W1S-MHC II tetramer-APC in a final concentration of 10 nM 
for 1  h at room temperature in the dark. Cells were washed, 
stained with monoclonal antibodies in a volume of 50  µl for 
30 min at 4°C and washed twice. Numbers of total cells, various 
cell types, and antigen-specific CD4+ T cells were determined 
using a Miltenyi MACSQuant® flow cytometer. After footpad 
injections, draining popliteal LNs were isolated 24  h later for 
flow cytometric analysis.
anti-Ovalbumin-specific elisa
96-well plates (Nunc MaxiSorp™, VWR) were coated with Ova 
(2 ng/µl in 100 mM NaHCO3, 33.6 mM Na2CO3, pH 9.5) at 4°C 
over night. Plates were washed thrice with 0.05% Tween 20/PBS 
and blocked with 200 µl 2% skimmed milk powder/PBS for 1 h 
at 37°C. Plates were washed thrice. Standards of anti-Ova IgG1 
and IgG2b (Thermo Scientific Fisher) ranging between 62,500 
and 122 pg/ml were generated by serial twofold dilutions. 100 µl/
well of standards and serum samples were pipetted into the Ova-
coated plates in doublets and incubated 1 h at 37°C. Plates were 
washed thrice. Secondary antibodies (HRP-labeled goat anti-
mouse IgG1, IgG2b, and IgG2c, Dianova) were diluted 1:10,000 
(anti-IgG1 and -IgG2b) or 1:2,000 (anti-IgG2c) and 100 µl/well 
were incubated 1 h at 37°C. After washing thrice, 100 µl freshly 
mixed substrate (BD OptEIA™) per well were added and plates 
were incubated for 15–30 min at RT in the dark. Reactions were 
stopped by adding 50  µl 2N H2SO4/well. Optical density was 
measured at 450 nm (reference value 570 nm) using a Sunrise™ 
spectral photometer. Magellan™ software was used for non-
linear regression analysis.
histology
Tail base skin was fixed in 4% formalin for 1 week and embedded 
in paraffin. Heads of mice were freed from skin, muscles, eyes, 
and lower jaw, fixed in 4% formalin for 1 week and decalcified 
in Osteosoft (Merck) for 2 weeks. After removing incisors and 
neurocranium, tissue was embedded in paraffin. Hindpaws were 
isolated by cutting in the middle of the tibia and removing the 
skin. The paws were fixed in 4% formalin for 1 week, decalcified in 
Osteosoft for 2 weeks and embedded in paraffin. LNs were fixed 
in Carnoy’s solution (ethanol:chloroform:acetic acid 6:3:1) over-
night followed by 8 h incubation in 100% ethanol and paraffin 
embedding. 5 µm paraffin sections were Giemsa-stained for MC 
quantification. Dermal MCs were counted per 20 mm horizontal 
length of epidermis. In frontal sections of the snout, MCs were 
counted in the connective tissue surrounding the NALT per 2 
high power fields centered on the right and left NALT and the 
mean of MC numbers on 15 sections/mouse was calculated. 
In the hindpaws, MCs were quantified around the tarsal bones 
per high power field centered on the tarsal bone. MC numbers 
were quantified for each hind paw of one mouse and the mean 
was calculated. For cytospins, cells from the peritoneal cavity 
were isolated by flushing with 5  ml ice cold PBS. Pellets were 
resuspended in 2% BSA/PBS and 200 µl were loaded per cuvette 
and spun at 800 rpm for 2 min in a cytocentrifuge (Shandon). Air-
dried slides were stained according to standard May-Grünwald 
and Giemsa protocols. Analysis was performed using Zeiss 
Axiovision Software.
statistical analysis
Data are shown as mean ± SD unless stated otherwise. For two-
group comparisons two-tailed Mann–Whitney test with 95% 
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confidence interval was used. For multi-group comparisons, 
Kruskal–Wallis with Dunn’s post-test (significance level α = 0.05) 
was performed. Time-course data were analyzed by two-way 
ANOVA with Bonferroni post-tests. Chi square test was used to 
analyze CIA incidence. Significance levels: *p < 0.05, **p < 0.01, 
and ***p < 0.001.
eThics sTaTeMenT
All procedures were in accordance with institutional guidelines 
on animal welfare and were approved by the Landesdirektion 
Dresden (DD24-5131/207/2 and DD24-5131/207/33).
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